IONS Collar Strategy
IONS (Ionis Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc.
IONS (Ionis Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $9.51B, a beta of 0.40 versus the broader market, a 52-week range of 41.71-86.74, average daily share volume of 2.5M, a public-listing history dating back to 1991, approximately 1K full-time employees. These structural characteristics shape how IONS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.40 indicates IONS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on IONS?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
IONS snapshot
As of August 14, 2026, spot at $56.90, ATM IV 44.20%, IV rank 9.07%, expected move 12.67%. The collar on IONS below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this collar structure on IONS specifically: IV regime affects collar pricing on both sides; compressed IONS IV at 44.20% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 12.67% (roughly $7.21 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IONS expiries trade a higher absolute premium for lower per-day decay. Position sizing on IONS should anchor to the underlying notional of $56.90 per share and to the trader's directional view on IONS stock.
IONS collar setup
The IONS collar below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IONS at $56.90 on that close, the first option leg uses a $60.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IONS chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IONS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $56.90 | long |
| Sell 1 | Call | $60.00 | $1.98 |
| Buy 1 | Put | $55.00 | $2.15 |
IONS collar risk and reward
- Net Premium / Debit
- -$5,707.50
- Max Profit (per contract)
- $292.50
- Max Loss (per contract)
- -$207.50
- Breakeven(s)
- $57.07
- Risk / Reward Ratio
- 1.410
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
IONS collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on IONS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$207.50 |
| $12.59 | -77.9% | -$207.50 |
| $25.17 | -55.8% | -$207.50 |
| $37.75 | -33.7% | -$207.50 |
| $50.33 | -11.5% | -$207.50 |
| $62.91 | +10.6% | +$292.50 |
| $75.49 | +32.7% | +$292.50 |
| $88.07 | +54.8% | +$292.50 |
| $100.65 | +76.9% | +$292.50 |
| $113.23 | +99.0% | +$292.50 |
When traders use collar on IONS
Collars on IONS hedge an existing long IONS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
IONS thesis for this collar
The market-implied 1-standard-deviation range for IONS extends from approximately $49.69 on the downside to $64.11 on the upside. A IONS collar hedges an existing long IONS position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current IONS IV rank near 9.07% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IONS at 44.20%. As a Healthcare name, IONS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IONS-specific events.
IONS collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IONS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IONS alongside the broader basket even when IONS-specific fundamentals are unchanged. Always rebuild the position from current IONS chain quotes before placing a trade.
Frequently asked questions
- What is a collar on IONS?
- A collar on IONS is the collar strategy applied to IONS (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With IONS stock at $56.90 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed IONS chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are IONS collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the IONS collar priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 44.20%), the computed maximum profit is $292.50 per contract and the computed maximum loss is -$207.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IONS collar?
- The breakeven for the IONS collar priced on this page is roughly $57.07 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IONS market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.67%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on IONS?
- Collars on IONS hedge an existing long IONS stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current IONS implied volatility affect this collar?
- IONS ATM IV is at 44.20% with IV rank near 9.07%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.